---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic impact on families"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic impact on families. Topics: Caregiver work changes and quality of life in 345 informal caregivers in the United States, United Kingdom, and Germany; Indirect costs of productivity loss for patients and family members, US employer claims; Systematic review of cancer treatment and work productivity of patients and caregivers; Workdays missed and indirect costs among employees with newly diagnosed metastatic versus non-metastatic cancer, US claims; 4 further topics. 8 evidence topics quoted from 8 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/economic-impact-on-families"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic impact on families

<a id="heading-2.2.1.8.3"></a>

## 2.2.1.8.3 Economic Impact of Previously treated ER-positive HER2-negative advanced or metastatic breast cancer on Families

<a id="topic-2.2.1.8.3-1"></a>

### Caregiver work changes and quality of life in 345 informal caregivers in the United States, United Kingdom, and Germany

> “We conducted a one-time, cross-sectional survey of 345 informal caregivers of people living with mBC in the United States, United Kingdom, and Germany in December 2021.”
> “One in three caregivers changed work status after onset of caregiving, either reducing working hours (12 %), stopping work altogether (13 %), or increasing working hours (8 %). Caregivers who reduced hours or stopped working reported better QoL overall with total CQOLC scores of 71.8 and 65.3, compared to those who maintained or increased work hours (CQOLC scores of 61.3 and 54.4, respectively, [p < 0.001]).”

Source: [Comerford et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39631724/)

<a id="topic-2.2.1.8.3-2"></a>

### Indirect costs of productivity loss for patients and family members, US employer claims

> “The MarketScan Health and Productivity Management database (2005-2009) was used.”
> “MBC patients had more sick leave cost than controls ($2383 ± $5539 vs. $1282 ± $2083, p < 0.05). Controlling for covariates, MBC patients incurred 47% more short-term disability costs vs EBC patients (p = 0.009).”
> “MBC patients' families incurred 39.7% (p = 0.06) higher indirect costs compared to EBC patients' families after controlling for key covariates.”

Source: [Wan et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23866016/)

<a id="topic-2.2.1.8.3-3"></a>

### Systematic review of cancer treatment and work productivity of patients and caregivers

> “Of 978 potential citations, 62 articles or abstracts were included. Forty-six studies (74.2%) evaluated patient-related productivity; 10 studies (16.1%) focused on caregivers, and 6 studies (9.7%) were a combination.”
> “The most commonly studied cancer was breast cancer (53.2%).”
> “Metastatic patients’ family members had higher leave days and associated costs than matched patients.”

Source: [Kamal et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10397748/)

<a id="topic-2.2.1.8.3-4"></a>

### Workdays missed and indirect costs among employees with newly diagnosed metastatic versus non-metastatic cancer, US claims

> “The mean total number of days missing from work for patients with versus without metastases was 33.39 versus 14.91 (ratio = 2.40), 64.05 versus 27.15 (ratio = 2.36), and 105.93 versus 46.29 (ratio = 2.29) days within 3, 6, and 12 months after diagnosis, respectively. Estimates of indirect cost differences between the two groups ranged from $6,877 to $22,283 in the first year.”

Source: [Cong et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9596506/)

<a id="topic-2.2.1.8.3-5"></a>

### Financial hardship by insurance status in 1054 women with metastatic breast cancer, US national survey

> “Participants responded from 41 states (N = 1054; median age: 44 years). Overall, 30% were uninsured.”
> “In adjusted analyses, uninsured participants were more likely than insured participants to report contact by debt collectors (adjusted risk ratio [aRR]: 2.38 [2.06, 2.76]) and being unable to meet monthly expenses (aRR: 2.11 [1.68, 2.66]). Financial distress was reported more frequently by insured participants.”
> “Young adult women with metastatic cancer reported a high burden of financial toxicity. Importantly, insurance does not protect against financial distress; however, the uninsured are the most materially vulnerable.”

Source: [Wheeler et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10242847/)

<a id="topic-2.2.1.8.3-6"></a>

### Drivers of financial burden and cost-coping behaviors: qualitative interviews with patients and caregiver representatives

> “A total of N=11 MBC patients or caregiver representatives participated in the study.”
> “Both medical and non-medical costs drove financial burden among participants. All participants reported challenges navigating their health insurance and applying for financial assistance. Regardless of gaining access to assistance, financial burden persisted for nearly all patients and resulted in cost-coping behaviors.”
> “Even when MBC patients accessed assistance, excess financial burden persisted necessitating use of financial coping-behaviors such as altering medication use, maintaining employment, and taking on debt.”

Source: [Waters et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11129926/)

<a id="topic-2.2.1.8.3-7"></a>

### Financial toxicity in 145 women with metastatic breast cancer at a US outpatient clinic

> “145 women with metastatic breast cancer receiving care at an urban outpatient breast cancer clinic.”
> “Financial toxicity is common among women with metastatic breast cancer and more common among low-income women with the disease. In addition, financial toxicity is correlated with worse quality of life and overall cancer-related distress.”

Source: [Rosenzweig et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30547962/)

<a id="topic-2.2.1.8.3-8"></a>

### Pooled rate of financial toxicity in breast cancer: meta-analysis of 66 studies

> “Sixty-six studies involving 29 426 participants with breast cancer were enrolled in our study.”
> “The pooled FT rate was 39.3% (95% CI, 32.4%-46.6%) in HICs and 72.3% (95% CI, 56.8%-83.8%) in LMICs.”

Source: [Yin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12831935/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
